Kristina Rowe
Psychiatric/Mental Health · Ironton, OHNPI 1528236262
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $201,407 of the $252,697 with a category attached, or 79.7%. Neurocrine Biosciences, Inc. accounts for 70.3% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $69,879, 2.5 times the $27,557 reported in 2021. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 742 payments — averaging $340.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$178K
- AbbVie$71K
- Lundbeck LLC$760
- Sunovion Pharmaceuticals Inc.$669
- Otsuka America Pharmaceutical, Inc.$521
- Takeda Pharmaceuticals U.S.A., Inc.$459
- plus $2K from 18 others
What the payments were for
- Consulting fees$21,1888%
- Speaking & faculty fees$201,40780%
- Travel & lodging$19,0148%
- Food & beverage$11,0884%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 191 | $177,535 |
| AbbVie(2 entities) | 222 | $70,624 |
| Lundbeck LLC | 80 | $760 |
| Sunovion Pharmaceuticals Inc. | 71 | $669 |
| Otsuka America Pharmaceutical, Inc. | 39 | $521 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $459 |
| Axsome Therapeutics, Inc. | 15 | $351 |
| Johnson & Johnson | 17 | $329 |
| Vanda Pharmaceuticals Inc. | 10 | $300 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $278 |
| Alkermes, Inc. | 11 | $236 |
| Teva Pharmaceuticals USA, Inc. | 7 | $130 |
| Corium, LLC | 7 | $109 |
| Ironshore Pharmaceuticals Inc. | 5 | $99 |
| Supernus Pharmaceuticals, Inc. | 6 | $82 |
| Indivior Inc. | 3 | $46 |
| GSK | 2 | $32 |
| Almatica Pharma LLC | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Braeburn Inc. | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$252,697 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $235,585 |
| VraylarCariprazine Hcl | 105 | $154,317 |
| RexultiBrexpiprazole | 32 | $58,249 |
| AuvelityDextromethorphan Hbr/Bupropion | 24 | $36,551 |
| TrintellixVortioxetine Hydrobromide | 20 | $23,385 |
| CaplytaLumateperone Tosylate | 11 | $17,986 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 59 | $5,051 |
| Aripiprazole | 17 | $4,311 |
| Lurasidone Hcl | 28 | $3,265 |
| Quetiapine Fumarate | 98 | $2,566 |
| Olanzapine | 83 | $2,546 |
| Duloxetine Hcl | 103 | $2,258 |
| Buspirone Hcl | 116 | $2,171 |
| Bupropion XlBupropion Hcl | 64 | $2,132 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $2,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $177,535 | $235,58529 claims |
| AbbVieVraylar | $70,624 | $154,317105 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $521 | $58,24932 claims |
| Axsome Therapeutics, Inc.Auvelity | $351 | $36,55124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $459 | $23,38520 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $278 | $17,98611 claims |
| Almatica Pharma LLCSertraline Hcl | $30 | $36497 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Ironton
- Crystal TravisJackson$333K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
- Tamara ThornMoraine$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.